Acquisition & Ownership Kanyos Bio operates as an affiliate within Anokion's corporate structure following an acquisition, providing a direct route into Anokion's immunology platform and access to pharma collaborators through Astellas for licensing or co-development discussions.

Strategic Partnerships Leverage the Anokion and Astellas network to pursue joint development or licensing deals around antigen-specific immune tolerance for type-1 diabetes and celiac disease; position as a specialized platform with potential cross-indication applicability.

Early-Stage Opportunity As an early-stage, pre-revenue biotech with venture funding, offer milestone-driven collaboration models appealing to pharma partners seeking risk-sharing, early access to proprietary tolerance technology, and potential speed to clinical impact.

Clinical Manufacturing Focus on translating science into clinical-scale processes; propose partnerships with CROs/CMOs and regulatory consultants to accelerate IND-enabling studies, GMP manufacturing readiness, and regulatory strategy.

Indication Focus Core emphasis on type-1 diabetes and celiac disease creates targeted outreach to potential collaborators, investors, and patient-focused groups seeking antigen-specific tolerance solutions and platform licensing opportunities.